CDK4/6 inhibitors are a new standard of care in the management of metastatic breast cancer patients. In the early setting, the use of genomic tests will better define the patients who will benefit the most from adjuvant chemotherapy.
Key Words
Breast cancer, CDK4/6 inhibitors, genomic tests
Please adapt your cookies preferences.
Operational cookies ensure the smooth running of the site and cannot be disabled.
The cookies optimization allows us to analyze the use of the site in order to improve it.
For more information, please read our cookies policy (FR)